Louisiana moves ahead with subscription model to pay for hepatitis C drugs for thousands

Louisiana is on track to become the first state to adopt a new method of obtaining normally pricey hepatitis C drugs — a move that health officials hope will ultimately help the state eradicate the deadly liver-damaging disease. State officials announced Thursday that Louisiana has begun the process of formally seeking a pharmaceutical partner for an innovative “subscription” model for obtaining treatments that cure hepatitis C — the nation's most deadly infectious disease.